We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Vertex Pharmaceuticals Inc | NASDAQ:VRTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.92 | 0.23% | 401.08 | 400.68 | 408.70 | 405.665 | 397.59 | 401.50 | 1,063,962 | 01:00:00 |
From Nov 2023 to May 2024
By Adriano Marchese
Vertex Pharmaceuticals said its treatment Kaftrio has been approved for a label expansion to treat children with cystic fibrosis in the European Union.
The pharmaceutical company said Thursday that the European Commission has granted approval for the label expansion of Kaftrio, also known as ivacaftor, tezacaftor and elexacaftor, in combination with ivacaftor to treat children between the ages of two and five with cystic fibrosis.
Chief Medical Officer Carmen Bozic said the decision was based on data from clinical trials as well as long-term and real-world data that have shown the clinical benefit of Kaftrio in eligible people who have CF.
Vertex said it already has a number of existing reimbursement agreements with European countries, and that it will continue to work with authorities to expand the list.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
November 23, 2023 09:39 ET (14:39 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Vertex Pharmaceuticals Chart |
1 Month Vertex Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
